Orogen Royalties Inc
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Clinical Trials
501
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (450 trials with phase data)• Click on a phase to view related trials
A Study to Investigate Efficacy and Safety of VTAMA® (Tapinarof) Cream, 1% in Plaque Psoriasis in the Head and Neck Region
- First Posted Date
- 2023-03-29
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 31
- Registration Number
- NCT05789576
- Locations
- 🇺🇸
Dermavant Investigative Site, Arlington, Texas, United States
🇺🇸Dermavant Investigative Sites, Rockville, Maryland, United States
Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients
- Conditions
- Atherosclerotic Cardiovascular Disease
- Interventions
- Drug: Atozet 10/40 mg or 10/80 mg
- First Posted Date
- 2023-03-09
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 137
- Registration Number
- NCT05761444
- Locations
- 🇰🇷
Eunpyeong St. Mary's Hospital, Seoul, Eunpyeong-gu, Korea, Republic of
🇰🇷Inje University Ilsan-Paik Hospital, Goyang, Gyeonggi-do, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
A Study to Investigate Efficacy and Safety of VTAMA (Tapinarof) Cream, 1% in Intertriginous Plaque Psoriasis
- First Posted Date
- 2023-01-11
- Last Posted Date
- 2025-06-12
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 34
- Registration Number
- NCT05680740
- Locations
- 🇺🇸
Dermavant Investigative Site, Webster, Texas, United States
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain
- First Posted Date
- 2022-09-29
- Last Posted Date
- 2025-05-29
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 354
- Registration Number
- NCT05560646
- Locations
- 🇺🇸
Central Research Associates LLC dba Flourish Research, Birmingham, Alabama, United States
🇺🇸UAB Center for Women's Reproductive Health, Birmingham, Alabama, United States
🇺🇸Olympia Clinical Trials, Los Angeles, California, United States
Contraceptive Efficacy and Safety of NOMAC-E2 Combined Oral Contraceptive
- Conditions
- Contraception
- Interventions
- Drug: NOMAC-E2 COC
- First Posted Date
- 2022-03-03
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 2007
- Registration Number
- NCT05264506
- Locations
- 🇺🇸
Alabama Clinical Therapeutics, LLC, Birmingham, Alabama, United States
🇺🇸SEC Clinical Research, Dothan, Alabama, United States
🇺🇸Alliance for Multispecialty Research, LLC, Norfolk, Virginia, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 101
- Next